S&P DJ Indices Announces March Quarterly Rebalance
Filed with ASX · · 8 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Preliminary Final Report
- Neuren announces new US patent to be granted for NNZ-2591
- Consolidation/Split - NEU
- Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
- Presentations and publication for Rett syndrome trials
Later from Neuren Pharmaceuticals
- Disclosure under Listing Rule 4.3D
- First patent in Japan granted for Neurens trofinetide
- Neuren announces investment and exclusive negotiation period
- Announcement of buy-back - Appendix 3C
- Neuren and ACADIA announce agreement for North America
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals